Theradiag SA (ALTHE) - Net Assets
Based on the latest financial reports, Theradiag SA (ALTHE) has net assets worth €-2.54 Million EUR (≈ $-2.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.55 Million ≈ $13.50 Million USD) and total liabilities (€14.09 Million ≈ $16.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALTHE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-2.54 Million |
| % of Total Assets | -21.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -100.02% |
| Growth Volatility | 569.66 |
Theradiag SA - Net Assets Trend (2001–2024)
This chart illustrates how Theradiag SA's net assets have evolved over time, based on quarterly financial data. Also explore Theradiag SA total assets for the complete picture of this company's asset base.
Annual Net Assets for Theradiag SA (2001–2024)
The table below shows the annual net assets of Theradiag SA from 2001 to 2024. For live valuation and market cap data, see ALTHE company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-114.00 ≈ $-133.28 |
-100.00% |
| 2023-12-31 | €5.65 Million ≈ $6.61 Million |
+937.66% |
| 2022-12-31 | €544.87K ≈ $637.01K |
+142.81% |
| 2021-12-31 | €-1.27 Million ≈ $-1.49 Million |
+60.71% |
| 2020-12-31 | €-3.24 Million ≈ $-3.79 Million |
-3962.44% |
| 2019-12-31 | €-79.73K ≈ $-93.21K |
+85.01% |
| 2018-12-31 | €-531.93K ≈ $-621.88K |
-115.33% |
| 2017-12-31 | €3.47 Million ≈ $4.06 Million |
-37.84% |
| 2016-12-31 | €5.58 Million ≈ $6.53 Million |
+637.61% |
| 2015-12-31 | €756.80K ≈ $884.78K |
-72.72% |
| 2014-12-31 | €2.77 Million ≈ $3.24 Million |
+172.95% |
| 2013-12-31 | €-3.80 Million ≈ $-4.45 Million |
-1377.67% |
| 2012-12-31 | €297.60K ≈ $347.92K |
+147.23% |
| 2011-12-31 | €120.37K ≈ $140.73K |
-90.57% |
| 2010-12-31 | €1.28 Million ≈ $1.49 Million |
-55.71% |
| 2009-12-31 | €2.88 Million ≈ $3.37 Million |
+535.20% |
| 2001-12-31 | €-662.00K ≈ $-773.95K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Theradiag SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 575711500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.32 Million | % |
| Other Components | €3.44 Million | % |
| Total Equity | €-114.00 | 100.00% |
Theradiag SA Competitors by Market Cap
The table below lists competitors of Theradiag SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wayi International Digital Entertainment Co
TWO:3086
|
$33.16 Million |
|
Mabion S.A.
WAR:MAB
|
$33.23 Million |
|
Creative Realities Inc
NASDAQ:CREX
|
$33.24 Million |
|
Chiu Ting Machinery Co Ltd
TW:1539
|
$33.26 Million |
|
Symphony Life Bhd
KLSE:1538
|
$33.15 Million |
|
TPC CONSOLIDATED LTD.
F:T7P
|
$33.15 Million |
|
WiseChip Semiconductor
TWO:5245
|
$33.15 Million |
|
TOP Engineering Co. Ltd
KQ:065130
|
$33.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theradiag SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,647,000 to -114, a change of -5,647,114 (-100.0%).
- Net loss of 5,757,000 reduced equity.
- New share issuances of 110,000 increased equity.
- Other comprehensive income increased equity by 4,815.
- Other factors decreased equity by 4,929.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.76 Million | -5050000.0% |
| Share Issuances | €110.00K | +96491.23% |
| Other Comprehensive Income | €4.82K | +4223.68% |
| Other Changes | €-4.93K | -4323.68% |
| Total Change | €- | -100.00% |
Book Value vs Market Value Analysis
This analysis compares Theradiag SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €0.43 | €0.48 | x |
| 2011-12-31 | €0.04 | €0.48 | x |
| 2012-12-31 | €0.10 | €0.48 | x |
| 2013-12-31 | €-1.27 | €0.48 | x |
| 2014-12-31 | €0.79 | €0.48 | x |
| 2015-12-31 | €0.19 | €0.48 | x |
| 2016-12-31 | €0.87 | €0.48 | x |
| 2017-12-31 | €0.46 | €0.48 | x |
| 2018-12-31 | €-0.06 | €0.48 | x |
| 2019-12-31 | €-0.01 | €0.48 | x |
| 2020-12-31 | €-0.20 | €0.48 | x |
| 2021-12-31 | €-0.06 | €0.48 | x |
| 2022-12-31 | €0.02 | €0.48 | x |
| 2023-12-31 | €0.12 | €0.48 | x |
| 2024-12-31 | €0.00 | €0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theradiag SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -693.61%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-324.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -150.09% | -899.23% | 0.05x | 3.06x | €-2.04 Million |
| 2011 | -1391.55% | -178.69% | 0.41x | 19.17x | €-1.69 Million |
| 2012 | -1032.53% | -102425200.00% | 0.00x | 10.74x | €-3.10 Million |
| 2013 | 0.00% | -5373.82% | 0.03x | 0.00x | €-3.73 Million |
| 2014 | -167.06% | -565.35% | 0.10x | 2.99x | €-4.91 Million |
| 2015 | -847.35% | -401.43% | 0.17x | 12.23x | €-6.49 Million |
| 2016 | -117.08% | -330.93% | 0.13x | 2.64x | €-7.09 Million |
| 2017 | -179.37% | -220.38% | 0.21x | 3.97x | €-6.57 Million |
| 2018 | 0.00% | -316.84% | 0.20x | 0.00x | €-6.09 Million |
| 2019 | 0.00% | -136.21% | 0.26x | 0.00x | €-3.78 Million |
| 2020 | 0.00% | -524.87% | 0.07x | 0.00x | €-3.58 Million |
| 2021 | 0.00% | -253.88% | 0.13x | 0.00x | €-3.63 Million |
| 2022 | -911.12% | -401.83% | 0.09x | 25.59x | €-5.02 Million |
| 2023 | -65.08% | -201.68% | 0.10x | 3.31x | €-4.24 Million |
| 2024 | 0.00% | -693.61% | 0.07x | 0.00x | €-5.76 Million |
Industry Comparison
This section compares Theradiag SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $20,945,054
- Average return on equity (ROE) among peers: -118.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theradiag SA (ALTHE) | €-2.54 Million | -150.09% | N/A | $33.15 Million |
| Affluent Medical SAS (AFME) | $58.87 Million | -9.92% | 0.05x | $110.43 Million |
| Biosynex (ALBIO) | $66.29 Million | 47.32% | 0.90x | $15.74 Million |
| Bluelinea SA (ALBLU) | $2.27 Million | -123.09% | 2.06x | $9.16 Million |
| Carmat (ALCAR) | $7.23 Million | -202.60% | 2.04x | $6.37 Million |
| Diagnostic Medical Systems SA (ALDMS) | $28.27 Million | -4.76% | 0.77x | $34.50 Million |
| Eurobio Scientific SA (ALERS) | $12.23 Million | -63.25% | 1.61x | $236.10 Million |
| Ikonisys SA (ALIKO) | $14.25 Million | -22.74% | 0.92x | $21.30 Million |
| Implanet SA (ALIMP) | $4.68 Million | -91.39% | 1.52x | $32.93 Million |
| Mediantechn (ALMDT) | $1.28 Million | -623.58% | 11.58x | $200.33 Million |
| Mauna Kea Technologies SAS (ALMKT) | $14.09 Million | -89.72% | 0.60x | $28.43 Million |
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more